

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier Trade name	:	Levamisole / Oxyclozanide Formulation
1.2 Relevant identified uses of t	the s	substance or mixture and uses advised against
Use of the Sub- stance/Mixture	:	Veterinary product
Recommended restrictions on use	:	Not applicable
1.3 Details of the supplier of the	e saf	ety data sheet
Company	:	MSD Kilsheelan Clonmel Tipperary, IE
Telephone	:	353-51-601000
E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Long-term (chronic) aquatic hazard, Cat-	H411: Toxic to aquatic life with long lasting effects.
egory 2	

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	H361d Suspected of damaging the unborn child.H411 Toxic to aquatic life with long lasting effects.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Levamisole / Oxyclozanide Formulation

Version 3.1	Revision Date: 28.09.2024	SDS Number: 5360533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
Preca	autionary statements	P273 Avoid rele	pecial instructions before use. ease to the environment. tective gloves/ protective clothing/ eye protec- on.
		Response: P308 + P313 IF attention. P391 Collect sp	F exposed or concerned: Get medical advice/
		Storage: P405 Store locl	ked up.
Haza	rdous components whi	ch must be listed on the	e label:

oxyclozanide

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
oxyclozanide	2277-92-1 218-904-0	Repr. 2; H361d STOT SE 2; H371 (Central nervous system) STOT RE 2; H373 (Brain, Liver) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute	>= 3 - < 10

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Levamisole / Oxyclozanide Formulation

Version 3.1	Revision Date: 28.09.2024	SDS Number: 5360533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019		
levan	nisole hydrochloride	16595-80-5	aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1 Acute Tox. 3; H301	>= 1 - < 2.5	
		240-654-6	Repr. 2; H361d STOT RE 2; H373 (Blood, Testis) Aquatic Chronic 3; H412	2- T \ 2,0	
Citric	acid	77-92-9 201-069-1 607-750-00-	Eye Irrit. 2; H319 STOT SE 3; H335 3	>= 1 - < 10	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks :	Suspected of damaging the unborn child.
---------	---

4.3 Indication of any immediate medical attention and special treatment needed

Commission Regulation (EU) 2020/878



Levamisole / Oxyclozanide Formulation

Version 3.1	Revision Date: 28.09.2024		DS Number: 60533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
Treat	ment	:	Treat symptomat	ically and supportively.
SECTIO	N 5: Firefighting meas	sur	es	
5.1 Exting	guishing media			
Suitable extinguishing media		:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical	
Unsuitable extinguishing media		:	None known.	
5.2 Speci	al hazards arising from	the	e substance or mi	xture
Specific hazards during fire- fighting		:	Exposure to combustion products may be a hazard to health.	
Hazardous combustion prod- ucts		:	Carbon oxides Chlorine compounds Nitrogen oxides (NOx)	
5.3 Advic	e for firefighters			
	Special protective equipment for firefighters			e, wear self-contained breathing apparatus. tective equipment.
Specific extinguishing meth- ods		:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do

6.1 Personal precautions, protective equipment and emergency procedures Personal precautions Use personal protective equipment.

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

6.3 Methods and material for containment and cleaning up

Meth	nods for cleaning up	:	Soak up with inert absorbent material. For large spills, provide dyking or other appropriate contain- ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

in i rooddallono for oaro nanaling	
Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not breathe mist or vapours.
	Do not swallow.
	Avoid contact with eyes.
	Avoid prolonged or repeated contact with skin.
	Wash skin thoroughly after handling.
	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment
	Do not eat, drink or smoke when using this product.
	Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use.
	The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
7.2 Conditions for safe storage, in	ncluding any incompatibilities

Requirements for storage areas and containers	:	Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents Gases



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

7.3 Specific end use(s)

Specific use(s)

: No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
oxyclozanide	2277-92-1	TWA	0.4 mg/m3 (OEB 2)	Internal
levamisole hydro- chloride	16595-80-5	TWA	20 µg/m3 (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm ²	Internal

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Citric acid	Fresh water	0,44 mg/l
	Marine water	0,044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34,6 mg/kg dry weight (d.w.)
	Marine sediment	3,46 mg/kg dry weight (d.w.)
	Soil	33,1 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection Hand protection		Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Material	:	Chemical-resistant gloves



Levamisole / Oxyclozanide Formulation

Version 3.1	Revision Date: 28.09.2024	SDS Number: 5360533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019				
Remarks Skin and body protection		: Work uniform Additional bod being performe suits) to avoid	 Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially 				
Respiratory protection Filter type		: If adequate loo sure assessme ommended gu Equipment sho	contaminated clothing. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143 Particulates type (P)				

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
рН	:	No data available
Viscosity Viscosity, kinematic	:	No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Levamisole / Oxyclozanide Formulation

Ver 3.1	sion	Revision Date: 28.09.2024		DS Number: 60533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
		lity(ies) ter solubility	:	No data availabl	e
		on coefficient: n- I/water	:	Not applicable	
	Vapou	r pressure	:	No data availabl	e
	Relativ	ve density	:	No data availabl	e
	Density		:	No data availabl	e
	Relative vapour density		:	No data availabl	e
		e characteristics ticle size	:	Not applicable	
9.2		nformation			
	Explos	ives	:	Not explosive	
	Oxidizi	ng properties	:	The substance c	or mixture is not classified as oxidizing.
	Evapo	ration rate	:	No data availabl	e
	Molecu	ular weight	:	No data availabl	e

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions						
Hazardous reactions	:	Can react with strong oxidizing agents.				

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

SECTION 11: Toxicological information

I Information on hazard class Information on likely routes of exposure		as defined in Regulation (EC) No 1272/2008 Inhalation Skin contact Ingestion Eye contact
Acute toxicity		
Not classified based on availa	ble	information.
Product:		
Acute oral toxicity	:	Acute toxicity estimate: > 2.000 mg/kg Method: Calculation method
Components:		
oxyclozanide:		
Acute oral toxicity	:	LD50 (Rat): 3.519 mg/kg Target Organs: Central nervous system
Acute toxicity (other routes of administration)	:	LDLo (sheep): 10 mg/kg Application Route: Intravenous
levamisole hydrochloride:		
Acute oral toxicity	:	LD50 (Rat): 180 mg/kg
		LD50 (Mouse): 223 mg/kg
		LD50 (Rabbit): 458 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available
Citric acid:		
Acute oral toxicity	:	LD50 (Mouse): 5.400 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 2.000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute derma toxicity
Skin corrosion/irritation		
Not classified based on availa	ble	information.

Components:

oxyclozanide:

Remarks

: Not classified due to lack of data.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

/ersion 5.1	Revision Date: 28.09.2024	SDS Number: 5360533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
levan	nisole hydrochloride	:	
Rema	ırks	: No data availa	able
Citric	acid:		
Speci	es	: Rabbit	
Metho Resul		: OECD Test G : No skin irritati	
Resu	l	. INO SKIN IMIAU	
Serio	us eye damage/eye	rritation	
Not cl	assified based on ava	ilable information.	
<u>Comp</u>	oonents:		
-	ozanide:		
Rema	ırks	: Not classified	due to lack of data.
levan	nisole hydrochloride	:	
Rema	•	: No data availa	able
	acid:	. Dahhit	
Speci Metho		: Rabbit : OECD Test G	uideline 405
Resul	t	: Irritation to ey	es, reversing within 21 days
Resp	iratory or skin sensi	tisation	
Skin	sensitisation		
Not cl	assified based on ava	ilable information.	
	iratory sensitisation		
	assified based on ava	illable information.	
<u>Com</u> p	oonents:		
-	ozanide:		
Expos Rema	sure routes irks	: Dermal : Not classified	due to lack of data.
	nisole hydrochloride		
Rema	urks	: No data availa	able
Germ	cell mutagenicity		
	assified based on ava	ilable information.	
Comp	oonents:		
oxvcl	ozanide:		
-	toxicity in vitro	: Test Type: Ba	cterial reverse mutation assay (AMES)

Commission Regulation (EU) 2020/878



Levamisole / Oxyclozanide Formulation

Version 3.1	Revision Date: 28.09.2024	SDS Numb 5360533-00		Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
		Test Ty	stem: Hum	nosomal aberration nan lymphocytes
		Test Ty Result:		Lymphoma
Ge	notoxicity in vivo	Species Applicat	pe: Micror : Mouse tion Route negative	ucleus test : Oral
		Species Cell type Applicat		
	rm cell mutagenicity- As- ssment	: Weight cell mut		e does not support classification as a germ
lev	amisole hydrochloride:			
Ge	notoxicity in vitro		pe: Bacter negative	ial reverse mutation assay (AMES)
			pe: Chrom negative	osome aberration test in vitro
Cit	ric acid:			
Ge	notoxicity in vitro		pe: Bacter negative	ial reverse mutation assay (AMES)
		Test Ty Result:		micronucleus test
			pe: Bacter negative	ial reverse mutation assay (AMES)
Ge	notoxicity in vivo	cytogen Species Applicat	etic test, c Rat	enicity (in vivo mammalian bone-marrow chromosomal analysis) : Ingestion
0.	roine gonicity			

Carcinogenicity

Not classified based on available information.

Components:

oxyclozanide:



ersion 1	Revision Date: 28.09.2024	SDS Number: 5360533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
Rema	rks	: Not classified	due to lack of data.
levam	isole hydrochloride	•	
Specie	es	: Mouse	
	ation Route	: Oral	
	sure time	: 2 Years	
NOAE		: 80 mg/kg body	/ weight
Rema			adverse effects were reported
Specie	es	: Rat	
	ation Route	: Oral	
	sure time	: 2 Years	
NOAE		: 40 mg/kg body	/ weight
Rema			adverse effects were reported
-	oductive toxicity	a unborn child	
-	onents:		
-	ozanide:		
Effect	s on fertility		o-generation reproduction toxicity study
			male and female
		Application Ro	
			ity - Parent: NOAEL: 25 - 35 mg/kg body weig
			educed body weight, No effects on embryofoet
		and postnatal	
		Result: No effe	ects on fertility
			o-generation reproduction toxicity study
		Species: Rat	
		Application Ro	
			ity - Parent: LOAEL: 75 - 100 mg/kg body
		weight	
			duced body weight, No effects on embryofoe
		and postnatal	
		Result: No effe	ects on tertility
		Test Type: Tw	o-generation reproduction toxicity study
		Species: Rat	
		Application Ro	oute: Oral
		Early Embryor	nic Development: LOAEL: 75 - 100 mg/kg bod
		weight	
		-	otoxicity, No teratogenic effects
			e-generation reproduction toxicity study
		Species: Rat	
		Application Ro	oute: Oral
			ity - Parent: LOAEL: 80 - 160 mg/kg body
		weight	
		Result: No feto	otoxicity, No teratogenic effects, No effects on
		fertility	



Versio 3.1		Revision Date: 28.09.2024		9S Number: 60533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019	
	Effects on foetal develop- ment		:			
			Test Type: Development Species: Rat Application Route: Oral General Toxicity Maternal: LOAEL: 100 mg/kg body we Result: No fetotoxicity, No teratogenic effects			
	Reproduc essmen	ctive toxicity - As- t	:	Suspected of dam	naging the unborn child.	
le	evamiso	ole hydrochloride:				
E	Effects on fertility		:	Species: Rat Application Route	generation reproduction toxicity study : Oral cant adverse effects were reported	
	Effects of nent	n foetal develop-	:	Species: Rat Application Route	oxicity: NOAEL: 20 mg/kg body weight	
				Species: Rabbit Application Route	oxicity: LOAEL: 40 mg/kg body weight	
	Reproducessmen	ctive toxicity - As- t	:	Some evidence of animal experimen	f adverse effects on development, based on ts.	
E	Citric ac Effects of nent	id: n foetal develop-	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion	

STOT - single exposure

Not classified based on available information.



rsion	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.20245360533-00013Date of first issue: 19.12.2019				
Comp	oonents:					
oxycl	ozanide:					
Expos	sure routes	: Oral				
	t Organs	: Central nervous system				
Asses	ssment	: May cause damage to organs.				
Citric	acid:					
Asses	sment	: May cause respiratory irritation.				
STOT	- repeated exposur	e				
Not cl	assified based on ava	ailable information.				
Comp	oonents:					
-	ozanide:					
-	t Organs	: Brain, Liver				
Asses	sment	: May cause damage to organs through prolonged or repeate exposure.				
levarr	nisole hydrochloride	•:				
	t Organs	: Blood, Testis				
Asses	ssment	: May cause damage to organs through prolonged or repeated exposure.				
Repe	ated dose toxicity					
<u>Comp</u>	oonents:					
	oonents: ozanide:					
oxycl	ozanide:	: Rat				
oxycl Speci NOAE	ozanide: es EL	: 9 mg/kg				
oxycl Speci NOAE LOAE	ozanide: es EL L	: 9 mg/kg : 44,5 mg/kg				
oxycl Speci NOAE LOAE Applic	ozanide: es EL EL cation Route	: 9 mg/kg : 44,5 mg/kg : Oral				
oxycl Specie NOAE LOAE Applic Expos	ozanide: es EL EL cation Route sure time	 9 mg/kg 44,5 mg/kg Oral 3 Months 				
oxycl Specie NOAE LOAE Applic Expos	ozanide: es EL Cation Route sure time t Organs	: 9 mg/kg : 44,5 mg/kg : Oral				
oxycl Specie NOAE LOAE Applic Expos Targe Symp	ozanide: es EL L cation Route sure time t Organs toms	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE	ozanide: es EL cution Route sure time t Organs toms es	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE LOAE	ozanide: es EL cation Route sure time t Organs toms es EL	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 25 mg/kg 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE LOAE Applic	ozanide: es EL cation Route sure time t Organs toms es EL cL cation Route	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 25 mg/kg Oral 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE LOAE Applic Expos	ozanide: es EL cation Route sure time t Organs toms es EL cation Route sure time	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 25 mg/kg Oral 3 Months 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE LOAE Applic Expos	ozanide: es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 25 mg/kg Oral 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE LOAE Applic Expos Targe Symp	ozanide: es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 25 mg/kg Oral 3 Months Brain, Liver blood effects, alteration in liver enzymes 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE LOAE Applic Expos Targe Symp	ozanide: es EL EL cation Route sure time t Organs toms es EL EL cation Route sure time t Organs toms	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 25 mg/kg Oral 3 Months Brain, Liver blood effects, alteration in liver enzymes 				
oxycl Specie NOAE LOAE Applic Expos Targe Symp Specie NOAE LOAE Applic Expos Targe Symp Ievam Specie NOAE	ozanide: es EL EL cation Route sure time t Organs toms es EL L cation Route sure time t Organs toms hisole hydrochloride es	 9 mg/kg 44,5 mg/kg Oral 3 Months Brain, Liver, spleen, Adrenal gland Liver effects Dog 5 mg/kg 25 mg/kg Oral 3 Months Brain, Liver blood effects, alteration in liver enzymes 				



Versio 3.1	on	Revision Date: 28.09.2024	-	DS Number: 660533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
		ire time Organs	:	18 Months Testis	
L A E	Exposu		:	Dog 20 mg/kg Oral 18 Months Blood	
L0 A			:	Dog 40 mg/kg Oral 3 Months	
S N LO A		S -	:	Rat 4.000 mg/kg 8.000 mg/kg Ingestion 10 Days	
	•	tion toxicity ssified based on availa	able	information.	
<u>C</u>	Compo	onents:			
	-	zanide: blicable			
11.2 lr	nform	ation on other hazar	ds		
E	Indoc	rine disrupting prope	ertie	s	
<u>P</u>	Produc	<u>et:</u>			
A	ssess	ment	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
E	xperi	ence with human exp	oosi	ure	
<u>C</u>	Compo	onents:			
0	xyclo	zanide:			
	ngestio		:	Symptoms: May nervous system of	cause, Gastrointestinal disturbance, Central depression
le	evami	sole hydrochloride:			
	ngestio	•	:	Symptoms: Naus tension	ea, Vomiting, Headache, Dizziness, hypo-



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

SECTION 12: Ecological information

12.1 Toxicity

Com	ponents:

oxyclozanide: Toxicity to daphnia and other aquatic invertebrates	:	Exposure time: 48 h
		Method: OECD Test Guideline 202
M-Factor (Acute aquatic tox- icity)	:	1
M-Factor (Chronic aquatic toxicity)	:	1
levamisole hydrochloride:		
Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): 37,3 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 64 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Citric acid:		
Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1.535 mg/l Exposure time: 24 h
12.2 Persistence and degradabil	lity	
Components:		
oxyclozanide:		
Stability in water	:	Hydrolysis: 50 %(156 d)
		Method: OECD Test Guideline 111
Citric acid:		
Biodegradability	:	Result: Readily biodegradable. Biodegradation: 97 % Exposure time: 28 d Method: OECD Test Guideline 301B

Commission Regulation (EU) 2020/878



Levamisole / Oxyclozanide Formulation

Version 3.1	Revision Date: 28.09.2024		DS Number: 360533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
12.3 Bioad	ccumulative potential			
Comp	oonents:			
-	ozanide:			
	ion coefficient: n- ol/water	:	log Pow: 3,99 pH: 7	
octan				est Guideline 107
Citric	acid:			
	ion coefficient: n- ol/water	:	log Pow: -1,72	
12.4 Mobi	lity in soil			
<u>Comp</u>	oonents:			
oxycl	ozanide:			
	oution among environ- al compartments	:	log Koc: 4,83 Method: OECD T	est Guideline 106
I2.5 Resu	Its of PBT and vPvB a	isse	essment	
<u>Produ</u>	uct:			
Asses	ssment	:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or not very bioaccumulative (vPvB) at levels of
12.6 Endo	ocrine disrupting prop	ertie	es	
Produ	uct:			
Asses	ssment	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
12.7 Othei	r adverse effects			

13.1 Waste treatment methods

Product

 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.



Version 3.1	Revision Date: 28.09.2024		OS Number: 60533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
Contan	Contaminated packaging		: Empty containers should be taken to an approved waste dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product	
SECTION	14: Transport infor	mat	ion	
14.1 UN nu	mber or ID number			
ADN		:	UN 3082	
ADR		:	UN 3082	
RID		:	UN 3082	
IMDG		:	UN 3082	
ΙΑΤΑ		:	UN 3082	
14.2 UN pro	oper shipping name			
ADN		:	ENVIRONMENT/ N.O.S. (oxyclozanide)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
ADR		:	ENVIRONMENT/ N.O.S. (oxyclozanide)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
RID		:	ENVIRONMENT/ N.O.S. (oxyclozanide)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
IMDG		:	ENVIRONMENT/ N.O.S. (oxyclozanide)	ALLY HAZARDOUS SUBSTANCE, LIQUID,
ΙΑΤΑ		:	Environmentally hazardous substance, liquid, n.o.s. (oxyclozanide)	
14.3 Transp	oort hazard class(es)			
			Class	Subsidiary risks
ADN		:	9	
ADR		:	9	
RID		:	9	
IMDG		:	9	
ΙΑΤΑ		:	9	
14.4 Packir	ng group			
Classifi	g group ication Code I Identification Number	:	III M6 90 9	



Levamisole / Oxyclozanide Formulation

Version 3.1	Revision Date: 28.09.2024		0S Number: 60533-00013	Date of last issue: 06.04.2024 Date of first issue: 19.12.2019
Class Hazaı Label	ng group ification Code rd Identification Number s el restriction code	:	III M6 90 9 (-)	
Class	ng group ification Code rd Identification Number s	:	III M6 90 9	
IMDG Packi Label EmS	ng group s	:	III 9 F-A, S-F	
Packi aircra Packi	ng instruction (LQ) ng group	:	964 Y964 III Miscellaneous	
Packi ger ai Packi	ng instruction (LQ) ng group	:	964 Y964 III Miscellaneous	
14.5 Envir	onmental hazards			
ADN Enviro	onmentally hazardous	:	yes	
ADR Enviro	onmentally hazardous	:	yes	
RID Enviro	onmentally hazardous	:	yes	
IMDG Marin	e pollutant	:	yes	
	(Passenger)	:	yes	
	(Cargo) onmentally hazardous	:	yes	
14.6 Spec	14.6 Special precautions for user			

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on Conditions of restriction for the fol-: the market and use of certain dangerous substances, lowing entries should be considered: Number on list 3 mixtures and articles (Annex XVII) Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor. Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not. REACH - Candidate List of Substances of Very High Not applicable : Concern for Authorisation (Article 59). REACH - List of substances subject to authorisation : Not applicable (Annex XIV) Regulation (EC) on substances that deplete the ozone Not applicable : laver Regulation (EU) 2019/1021 on persistent organic pollu-Not applicable : tants (recast) Regulation (EU) No 649/2012 of the European Parlia-Not applicable : ment and the Council concerning the export and import of dangerous chemicals Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances. Quantity 1 Quantity 2

		a a a a a a a a a a a a a a a a a a a	
E2	ENVIRONMENTAL	200 t	500 t
	HAZARDS		

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined



Levamisole / Oxyclozanide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information				
Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.		
Full text of H-Statemen	ts			
H301	:	Toxic if swallowed.		
H319	:	Causes serious eye irritation.		
H335	:	May cause respiratory irritation.		
H361d	:	Suspected of damaging the unborn child.		
H371	:	May cause damage to organs if swallowed.		
H373	:	May cause damage to organs through prolonged or repeated exposure.		
H373	:	May cause damage to organs through prolonged or repeated exposure if swallowed.		
H400	:	Very toxic to aquatic life.		
H410	:	Very toxic to aquatic life with long lasting effects.		
H412	:	Harmful to aquatic life with long lasting effects.		
Full text of other abbre	viations			
Acute Tox.	:	Acute toxicity		
Aquatic Acute	:	Short-term (acute) aquatic hazard		
Aquatic Chronic	:	Long-term (chronic) aquatic hazard		
Eye Irrit.	:	Eye irritation		

	-	
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure
STOT SE	:	Specific target organ toxicity - single exposure
ADN - European Agreement concerning the International Carriage of Dangerous Goods b		

by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road: AIIC - Australian Inventory of Industrial Chemicals: ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified;



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	5360533-00013	Date of first issue: 19.12.2019

NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Aquatic Chronic 2

Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/	
Classification of the mixture	e:	Classification procedure:	
Repr. 2	H36	1d Calculation method	

Calculation method

H411

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN